Outcomes of therapy with venetoclax combined with a hypomethylating agent in favorable-risk acute myeloid leukemia

Am J Hematol. 2021 Mar 1;96(3):E59-E63. doi: 10.1002/ajh.26057. Epub 2020 Dec 8.

¹ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
² Department of Information Sciences, City of Hope Medical Center, Duarte, California, USA.
³ Department of Hematology and Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA.
⁴ Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁵ Jane Anne Nohl Division of Hematology and Center for the study of Blood disease, University of Southern California, Los Angeles, California, USA.

No abstract available

Publication types